KayoThera has taken part in the NYU Stern Business School Endless Frontier Labs accelerator program since October 2020 to refine the business plan and expand the company trajectory and growth initiatives. This accelerator was exceptionally valuable to the development...
Kayothera founders Dr. Esposito and Dr. Kang as well as Scientific Advisory Board Member Dr. Ganesan today published a perspective on the clinical need for new therapeutics treating advanced cancer patients in Nature Cancer. While many therapies have been developed...
In the cover article of the March issue of Nature Cell Biology, Dr. Mark Esposito and Dr. Yibin Kang announce the discovery of a novel driver of breast and prostate cancer metastasis. This newly discovered organelle is driven by a relatively unknown protein named...
KayoThera will be presenting at this year’s 10th Annual BioNJ Biopartnering Conference. Please join us Tuesday, October 6 & Wednesday, October 7, 2020.
Kayothera, an early-stage therapeutics company and Princeton University spinout, is working to give hope to some of the most vulnerable cancer patients. Now the company’s aspirations are being bolstered by significant seed funding received from the New Jersey Health...